-
Rexahn Pharmaceuticals Completes Patient Enrollment in Serdaxin Phase IIb Clinical Trial for Major Depressive Disorder
Wednesday, June 22, 2011 - 8:02am | 149Rexahn Pharmaceuticals (NYSE: RNN) today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder. The randomized, double blind, and placebo-controlled study began enrollment in January 2011 and enrolled a total of 300 patients at...
-
Citadel Securities Reiterates Neutral Rating On Savient Pharmaceuticals
Wednesday, June 22, 2011 - 7:59am | 124According to Citadel Securities, Savient Pharmaceuticals (NASDAQ: SVNT) Neutral rating is reiterated. Citadel Securities said that the FDA's Arthritis Drugs Advisory Committee voted 11-1 against approval of Novartis' Ilaris for the treatment of gout flares in patients with an inadequate response...
-
UPDATE: Jefferies Color on Nanosphere PT Decrease
Wednesday, June 22, 2011 - 7:54am | 100Jefferies, which lowered its PT on shares of Nanosphere (NASDAQ: NSPH), is providing some color on the stock. “We are lowering our 2011 and 2012 revenue forecasts to $3.3M (from $4.5M) and $9M (from $17M), respectively, to reflect the CYP2C19 setback and the impact of fewer new Verigene system...
-
Global Hunter Initiates MediciNova At Buy, $4 PT
Wednesday, June 22, 2011 - 7:36am | 25Global Hunter Securities has initiated coverage on MediciNova (NASDAQ: MNOV) with a Buy rating and $4 price target.
-
Pharmasset Announces Issuance of U.S. Patent for PSI-7977
Wednesday, June 22, 2011 - 6:52am | 127Pharmasset, Inc. (Nasdaq: VRUS) announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 ("the '580 patent") titled "Nucleoside Phosphoramidate Prodrugs". This patent generally relates to the composition of matter of PSI-7977 and its diastereomeric mixture for...
-
Jefferies Lowers PT On Nanosphere To $2
Wednesday, June 22, 2011 - 6:10am | 26Jefferies & Company has lowered the price target on Nanosphere (NASDAQ: NSPH) from $3.50 to $2 and maintains its Hold rating.
-
Aastrom Establishes Independent Steering Committee for REVIVE Phase 3 CLI Clinical Program
Tuesday, June 21, 2011 - 4:16pm | 95Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced the formation of an independent steering committee to support the REVIVE Phase 3 clinical program for ixmyelocel-T, the company's expanded multi-cellular product. The committee includes renowned leaders in vascular medicine and clinical...
-
Threshold Pharmaceuticals Announces Completion of Patient Recruitment for Phase 2 TH-302 Pancreatic Cancer Study
Tuesday, June 21, 2011 - 4:16pm | 156Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), announced today the completion of patient enrollment into the Company's Phase 2 pancreatic cancer study with TH-302, a novel small molecule tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia and is applicable to a broad...
-
Threshold Pharmaceuticals Announces Completion of Patient Recruitment for Phase 2 TH-302 Pancreatic Cancer Study
Tuesday, June 21, 2011 - 4:15pm | 89Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), announced today the completion of patient enrollment into the Company's Phase 2 pancreatic cancer study with TH-302, a novel small molecule tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia and is applicable to a broad...
-
Rodman & Renshaw Outperform On Curis, Inc.
Tuesday, June 21, 2011 - 1:56pm | 139Rodman & Renshaw has an Outperform rating and a $6 price target on shares of Curis, Inc. (NASDAQ: CRIS). In a note to clients, Rodman & Renshaw writes, "We are reiterating our Market Outperform / Speculative Risk rating and a 12-month target price of $6. Our price target is derived from a...
-
PharmAthene Now Up 27%
Tuesday, June 21, 2011 - 12:47pm | 76Shares of small-cap biotech company PharmAthene (AMEX: PIP) are now trading around 27% higher at $3.07. The stock was highlighted on SeekingAlpha yesterday, and could be a beneficiary of a lawsuit that the company is engaged in with Siga Technologies (NASDAQ: SIGA). PharmAthene, Inc. is a...
-
Puts Purchased on Cubist Pharmaceuticals, Inc.
Tuesday, June 21, 2011 - 12:45pm | 110Shares of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) are higher on the session by 0.59%, currently trading at $35.89. The stock has been moving largely higher over the past six months and is currently trading above the 200-day moving average. Options traders are buying puts on the name today....
-
Pharmathene up 24% on Reports of Insider Buying
Tuesday, June 21, 2011 - 11:12am | 48Shares of Pharmathene Inc (NYSE: PIP) is up 24% on reports of insider buying. Company's director bought 17,850 shares at $2.69 on June 17. PharmAthene, Inc. is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons.
-
Calls Purchased on Acorda Therapeutics, Inc.
Tuesday, June 21, 2011 - 11:09am | 135Shares of Acorda Therapeutics, Inc. (NASDAQ: ACOR) are higher on the session by 2.01%, currently trading at $32.00. The stock has been moving largely higher over the past three months and is currently trading above the 200-day moving average. Options traders are buying calls on the name today....
-
Biogen Idec Trading Nearly 2% Higher on Deutsche Bank Upgrade
Tuesday, June 21, 2011 - 10:47am | 40Biogen Idec (NASDAQ: BIIB) is trading nearly 2% higher on the Deutsche Bank's "Buy" upgrade earlier this morning. BIIB is currently trading at $100.62 per share. Biogen Idec Inc. is a global biotechnology company.